Bone Biologics Corp (BBLG)

Oct 21, 2024, 8:00 AM EDT - 5 months ago

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Sep 4, 2024, 8:00 AM EDT - 7 months ago

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 2, 2024, 8:00 AM EDT - 8 months ago

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Jun 20, 2024, 8:00 AM EDT - 10 months ago

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

Mar 6, 2024, 4:15 PM EST - 1 year ago

Bone Biologics Announces Closing of $2.0 Million Public Offering

Mar 4, 2024, 9:15 AM EST - 1 year ago

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Mar 1, 2024, 8:00 AM EST - 1 year ago

Bone Biologics Reports Progress With NB1 Clinical Program

Jan 11, 2024, 8:00 AM EST - 1 year ago

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

Jan 10, 2024, 8:00 AM EST - 1 year ago

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Dec 18, 2023, 8:00 AM EST - 1 year ago

Bone Biologics Announces 1-for-8 Reverse Stock Split

Nov 20, 2023, 12:38 PM EST - 1 year ago

Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 4:43 PM EST - 1 year ago

Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Bone Biologics Provides Scientific Update on NB1 Bone Graft Device

Jun 21, 2023, 7:49 AM EDT - 1 year ago

Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)

FRES VTGN

Jun 15, 2023, 9:22 AM EDT - 1 year ago

Bone Biologics stock plummets more than 50% after stock offering prices at deep discount

Jun 14, 2023, 11:30 PM EDT - 1 year ago

Bone Biologics Prices $5.0 Million Underwritten Public Offering

Jun 6, 2023, 1:00 PM EDT - 1 year ago

Bone Biologics Effects 1-for-30 Reverse Stock Split

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

Jan 26, 2023, 8:30 AM EST - 2 years ago

Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

Oct 25, 2022, 8:00 AM EDT - 2 years ago

Bone Biologics CEO Issues Letter to Stockholders

Oct 13, 2022, 9:00 AM EDT - 2 years ago

WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering

Oct 12, 2022, 4:05 PM EDT - 2 years ago

Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

Oct 7, 2022, 10:52 AM EDT - 2 years ago

CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering

Oct 7, 2022, 10:16 AM EDT - 2 years ago

WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering

Oct 7, 2022, 8:00 AM EDT - 2 years ago

Bone Biologics Prices $5,100,000 Million Underwritten Public Offering

Mar 23, 2022, 8:00 AM EDT - 3 years ago

Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Mar 7, 2022, 7:00 AM EST - 3 years ago

Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix

Jan 10, 2022, 10:38 AM EST - 3 years ago

Why Are Bone Biologics Shares Surging On Monday?

Jan 5, 2022, 8:30 AM EST - 3 years ago

Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference

Oct 18, 2021, 8:30 AM EDT - 3 years ago

Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq

Oct 15, 2021, 12:00 PM EDT - 3 years ago

WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering

Oct 13, 2021, 1:43 PM EDT - 3 years ago

WallachBeth Capital announces pricing of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering and Uplisting to the NASDAQ Capital Market

Oct 13, 2021, 12:25 PM EDT - 3 years ago

Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split